Revised SPC: Ocrevus (ocrelizumab) 300 mg concentrate for solution for infusion

SPC updated to include case reports of late onset of neutropenia (frequency unknown) at least 4 weeks after the latest infusion. In patients with signs and symptoms of infection, measurement of blood neutrophils is recommended.

electronic Medicines compendium